Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions
- 04 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Mar 2026.
- 04 Feb 2025 Planned initiation date changed from 30 Dec 2024 to 30 Mar 2025.
- 25 Nov 2024 Planned initiation date changed from 1 Oct 2024 to 30 Dec 2024.